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Background: Encapsulating peritoneal sclerosis (EPS) is a rare surgical complication that can occur after
intraperitoneal treatment. It is also a serious and potentially fatal complication of continuous ambulatory peritoneal
dialysis. The present report describes a case of surgically treated EPS that probably occurred as a complication of
hyperthermic intraperitonal chemotherapy (HIPEC).
Case presentation: A 39-year-old man required sigmoidectomy for serosal invasive advanced sigmoid colon
cancer. HIPEC with oxaliplatin, 5-fluorouracil and mitomycin C were given as adjuvant therapy. Subsequently,
intestinal obstruction developed at 15 months postoperatively, and the patient was hospitalized. Abdominal
computed tomography showed a dilated small intestine enveloped by a thickened membrane. We found no
evidence of peritoneal recurrence, but exploratory surgery revealed EPS, probably caused by HIPEC. We peeled the
capsule off of the intestine. The patient’s postoperative course was uneventful, and sufficient nutritional intake after
surgery was noted. Seven months after surgery, he is well with no recurrence.
Conclusion: The surgical treatment via peritonectomy and enterolysis for postoperative EPS appears safe and
effective. A diagnosis of EPS should be considered when intestinal obstruction does not show improvement with
conservative treatment in patients who have undergone HIPEC, provided the possibility of peritoneal cancer
recurrence is excluded.
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peritonitisBackground
The use of cytoreductive surgery combined with hy-
perthermic intraperitoneal chemotherapy (HIPEC) is a
novel approach that offers improved survival after peri-
toneal surface malignancy, including colorectal periton-
eal metastases (PM) [1-3]. HIPEC is also an attractive
option for the treatment of patients at high risk of devel-
oping PM after surgical management of advanced colo-
rectal cancer [4,5]. We previously conducted a phase I* Correspondence: hirosono@belle.shiga-med.ac.jp
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colorectal cancer in patients who were at high risk of
developing PM after surgery [4]. However, HIPEC is as-
sociated with an increased risk of surgical complications
and toxicity. Canda et al. described the morbidity and
mortality rates after HIPEC [6]. Complications of such
therapy may include nephrotoxicity, hemotoxicity, post-
operative hemorrhage, anastomotic leakage, intestinal per-
foration, and wound complications. Awareness and early
recognition of the surgical complications and toxicity of
this approach may help reduce mortality rates.
Encapsulating peritoneal sclerosis (EPS) is a rare sur-
gical complication that can occur after intraperitonealntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Abdominal computed tomography shows a dilated
and filled small intestine enveloped by a thickened
membrane (arrow).
Figure 2 Operative findings showed small intestine covered by
white and fibrous membrane. The small intestine is partially
covered by a white membrane and looks like a cocoon. The fibrous
membrane is peeled off to release the small intestine.
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http://www.biomedcentral.com/1471-2482/14/57treatment. It is also a serious and potentially fatal com-
plication of continuous ambulatory peritoneal dialysis
(CAPD) [7]. Some reports have described EPS occurring
after intraperitoneal chemotherapy (IPC), and EPS is
considered as a delayed complication of IPC or HIPEC
[7,8]. The present report describes a case of surgically
treated EPS that probably occurred as a complication of
HIPEC.
Case presentation
A 39-year-old man with serosal invasive advanced sigmoid
colon cancer underwent surgery at Shiga University of
Medical Science Hospital. Sigmoidectomy with regional
lymph node dissection followed by reconstruction with
stapled functional end-to-end anastomosis was performed.
HIPEC was subsequently delivered as described previously
[4]. Briefly, the laparotomy incision was closed until an
18-cm opening. An Alexis Wound Retractor (Applied
Medical Resource, CA, USA) and plastic cylinder were
used to make a waterbath space for HIPEC. A perfusate of
5 L saline solution (Otsuka Pharmaceutical Factory,
Tokushima, Japan) was circulated at flow rate of 500–
750 mL/min by using the CP-3000 system (Tonokura,
Tokyo, Japan). After the temperature of the perfusate
reached 42-43°C, 10 mg of mitomycin-C, 1000 mg of
5-fluorouracil, and 200 mg of oxaliplatin was added.
HIPEC was performed for 30 minutes after the addition of
the anti-tumor drugs. We stirred the perfusate manually
and extensively to strictly maintain the temperature of the
abdominal perfusate between 42 and 43°C. Histological
examination revealed moderately differentiated adenocar-
cinoma without lymph node metastasis. The disease was
classified as stage II, T4N0M0 according to the TNM clas-
sification. The number of dissected lymph nodes was 10
at this operation. There were no postoperative complica-
tions, and 4 days after the operation, he started oral intake.
He was discharged from hospital on the 8th postoperative
day. He received adjuvant chemotherapy with oral cape-
citabine administration for 3 months after surgery.
Approximately 15 months after surgery, the patient
presented to our hospital complaining of nausea, abdo-
minal distention, and abdominal pain. His body weight
had decreased from 60 kg at the time of initial surgery
to 50 kg. Levels of the tumor markers, carcinoembryonic
antigen and carbohydrate antigen 19–9, were within
normal range. Abdominal x-ray showed increased intes-
tinal gas and gas-fluid levels. He was admitted to the
hospital with a diagnosis of adhesive intestinal obstruc-
tion. Abdominal computed tomography (CT) scan showed
a dilated small intestine enveloped by a thickened mem-
brane (Figure 1). After admission, we diagnosed as EPS
based on these data. He was treated with decompression
via long intestinal tube and with intravenous betametha-
sone administration. After 3 days, intestinal obstructiondid not improve with such conservative treatments. Lapar-
otomy was performed, showing most of the small intestine
folded and extensively enveloped by a thickened mem-
brane, with the appearance of a cocoon (Figure 2). No pe-
ritoneal nodule was found, and cytological examination of
the peritoneal washing did not show any cancer cells. No
signs of peritoneal recurrence were found. Incision of the
thickened membrane surrounding the small intestine con-
firmed that the serosa of the small intestine was normal
without any cancer invasion. The procedure was per-
formed easily, except in the terminal ileum where there
was tight adhesion and round fibrous stenosis. The round
fibrous thickening of the small intestine was alleviated
by incising the surrounding thickened membrane. There
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rence of intestinal obstruction. Seven days after the oper-
ation, he started oral intake. He was discharged from
hospital on the 18th postoperative day. Histological find-
ings of the thickened membrane showed proliferation
of fibroconnective tissue and inflammatory infiltrates
(Figure 3a, b). No histological signs of peritoneal re-
currence were found. Seven months after surgery, he is
well, with no radiological signs or laboratory evidence of
recurrence, and his body weight has increased back to that
observed in the preoperative state.
This report described a rare case of EPS after HIPEC
that was successfully treated via the surgical approach.
EPS causes intestinal obstruction, because the small in-
testine is enveloped by a secondary thick fibrosis. Several
report showed the morbidity rates after HIPEC were
20.8-53.3% [6]. Major complications may include ne-
phrotoxicity, hemotoxicity, postoperative hemorrhage,
anastomotic leakage, intestinal perforation, and wound
complications [6]. EPS is a rare surgical complication
that can occur after HIPEC. The cause is still unclear,
although several factors have been implicated, including
CAPD treatment for chronic renal failure and a past
history of peritonitis or cirrhotic ascites [9]. Only one
report describes the occurrence of EPS as a delayed
complication of HIPEC [7].
Previously, 9 cases of EPS after IPC and 1 case of EPS
after HIPEC were reported (Table 1) [7,8,10,11]. Most of
the cases developing EPS underwent intraperitoneal
chemotherapy including platinums. One of the possible
causes of EPS in patients undergoing CAPD is related to
the low pH of the dialysate [7]. The incidence of EPS de-
creases in response to agents that neutralize the pH of
the dialysate [7]. In our method, the optimal pH for
Oxaliplatin ranges from approximately 4.0 to 7.0 [4], and
this acidity might contribute to the development of EPS.
An intraperitoneal temperature of 42-43°C is necessary
to obtain the maximal therapeutic effects of HIPEC [7].
Previous reports have described EPS occurred even among
patients treated by normothermia [8,10]. Shindo et al.Figure 3 Histological features of the case. (a), (b) Histological findings o
tissue and inflammatory infiltrates.reported that peritoneal damage was not dissimilar be-
tween patients given HIPEC and those given continuous
normothermic peritoneal perfusion using 37.0°C perfusate
[12]. However, hyperthermia induced intracellular acidosis
[13] and may accelerate instability in intracellular pH.
Thus, we consider hyperthermia may be a cause of EPS.
Steroid therapy is considered to be effective for pre-
venting EPS, because the “second hit” in development of
EPS may be related to various cytokines. The second hit
theory whereby dialysis fluids contribute to peritoneum
damage. Cases of peritoneal dialysis-related EPS have
responded favorably to corticosteroid therapy alone [9].
In our case, however, steroid therapy was not effective.
In our case, incision and resection of the sclerosing
peritoneum resulted in improvement of stenosis without
postoperative complications. It is important that the en-
terolysis is performed without damaging the encapsu-
lated intestine. The overall morbidity rate of surgery for
EPS is reported as approximately 60% [14]. However,
Kawanishi et al. reported successful treatment of 18 pa-
tients with CAPD-related EPS and suggested that perito-
nectomy and enterolysis for EPS was a useful therapeutic
method [15]. They emphasized the critical role of early
diagnosis of EPS as well as determination of the thera-
peutic strategy according to the disease stage. In three pa-
tients, EPS was relieved by steroid therapy. In 15 patients,
EPS was relieved by total intestinal enterolysis. These pa-
tients had satisfactory operative outcomes and returned to
their previous activity. Ulmer et al. reviewed 26 patients
with EPS who underwent peritonectomy and enterolysis
[16]. They suggested that this treatment option could be
performed with low mortality and acceptable morbidity.
Thus, peritonectomy and enterolysis are considered to be
appropriate methods for EPS induced by HIPEC in a man-
ner similar to that for EPS induced by CAPD.
Conclusion
Preoperative distinction among adhesion, EPS, or PM
can be difficult when small bowel obstruction occurs in
patients who have received HIPEC. A diagnosis of EPSf the thickened membrane show proliferation of fibroconnective
Table 1 Reported cases of encapsulating peritoneal sclerosis after intraperitoneal chemotherapy treated by the surgical approach
No Authors Year Age
(years)










1 Braly [11] 1986 Unknown Female Ovarian cancer Cisplatin, 5-fluorouracil No Unknown Laparotomy No Unknown Unknown
2 Braly [11] 1986 Unknown Female Ovarian cancer Cisplatin, 5-fluorouracil No Unknown Laparotomy No Unknown Unknown
3 Braly [11] 1986 Unknown Female Ovarian cancer Cisplatin, 5-fluorouracil No Unknown Laparotomy No Unknown Unknown
4 Vlasveld [10] 1992 44 Male Mesothelioma Metoxantrone No 24 months Surgery No No Alive, 48 months
5 Atiq [8] 1993 Unknown Unknown Gastric cancer Cisplatin, 5-fluorouracil No 4 to 17.5 months Surgery No No Unknown
6 Atiq [8] 1993 Unknown Unknown Gastric cancer Cisplatin, 5-fluorouracil No 4 to 17.5 months Surgery No No Unknown
7 Atiq [8] 1993 Unknown Unknown Gastric cancer Cisplatin, 5-fluorouracil No 4 to 17.5 months Surgery No No Unknown
8 Atiq [8] 1993 Unknown Unknown Gastric cancer Cisplatin, 5-fluorouracil No 4 to 17.5 months Surgery No Yes Unknown
9 Atiq [8] 1993 Unknown Unknown Gastric cancer Cisplatin, 5-fluorouracil No 4 to 17.5 months Laparotomy Yes Unknown Unknown
10 Aihara [7] 2003 47 Female Gastric cancer Cisplatin, mitomycin-C Yes 6 months Surgery No No Alive, 21 months
11 Our case 2014 39 Male Colon cancer Oxaliplatin, 5-fluorouracil,
mitomycin-C
Yes 16 months Surgery, oral
steroid therapy
No No Alive, 24 months
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http://www.biomedcentral.com/1471-2482/14/57should be considered if intestinal obstruction does not
show improvement with conservative treatment, pro-
vided that the possibility of PM is excluded. Early lapar-
otomy and resection of thickening fibrosis are important
to improve the patient’s quality of life. In addition, on-
going efforts to increase the feasibility and safety of in-
traperitoneal chemotherapy are warranted.
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